Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30

$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Earnings

Vaxart's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Mar 11, 2027

Q4 FY2026 · estimated, during market hours

Revenue, Q3 FY2026

$10.60M

-85.4% on a year earlier

EPS, Q3 FY2026

-$0.07

-$0.04 a year earlier

Latest guidance

None

No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Vaxart's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Dec 31, 2026	Mar 11, 2027Expected	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Nov 5, 2026after the close	$10.60M	-85.4%	-$0.07	Release
Q2 FY2026ended Jun 30, 2026	Aug 6, 2026during market hours	$27.20M	-31.5%	-$0.06	Release
Q1 FY2026ended Mar 31, 2026	May 7, 2026during market hours	$39.20M	+87.6%	$0.02	Release
Q4 FY2025ended Dec 31, 2025	Mar 12, 2026during market hours	–	–	–	Release
Q3 FY2025ended Sep 30, 2025	Nov 13, 2025during market hours	$72.40M	+1377.6%	-$0.04	Release
Q2 FY2025ended Jun 30, 2025	Aug 13, 2025during market hours	$39.70M	–	-$0.07	Release
Q1 FY2025ended Mar 31, 2025	May 13, 2025during market hours	$20.90M	–	-$0.07	Release
Q4 FY2024ended Dec 31, 2024	Mar 21, 2025during market hours	–	–	–	Release
Q3 FY2024ended Sep 30, 2024	Nov 13, 2024during market hours	$4.90M	–	-$0.06	Release
Q2 FY2024ended Jun 30, 2024	Aug 8, 2024during market hours	–	–	–	Release
Q1 FY2024ended Mar 31, 2024	May 13, 2024during market hours	–	–	–	Release
Q4 FY2023ended Dec 31, 2023	Mar 14, 2024during market hours	–	–	–	Release
Q3 FY2023ended Sep 30, 2023	Nov 2, 2023during market hours	–	–	–	Release
Q2 FY2023ended Jun 30, 2023	Aug 3, 2023during market hours	–	–	–	Release
Q1 FY2023ended Mar 31, 2023	May 9, 2023during market hours	–	–	–	Release
Q4 FY2022ended Dec 31, 2022	Mar 16, 2023during market hours	–	–	–	Release
Q3 FY2022ended Sep 30, 2022	Nov 8, 2022during market hours	–	–	–	Release
Q2 FY2022ended Jun 30, 2022	Aug 8, 2022during market hours	–	–	–	Release
Q1 FY2022ended Mar 31, 2022	May 10, 2022during market hours	–	–	–	Release
Q4 FY2021ended Dec 31, 2021	Feb 24, 2022during market hours	–	–	–	Release
Q3 FY2021ended Sep 30, 2021	Nov 4, 2021during market hours	–	–	–	Release
Q2 FY2021ended Jun 30, 2021	Aug 2, 2021during market hours	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 3, 2021before the open	–	–	–	Filing
Q3 FY2020ended Sep 30, 2020	Oct 14, 2020before the open	–	–	–	Filing
Q2 FY2020ended Jun 30, 2020	Jul 8, 2020before the open	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Vaxart has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Vaxart puts a forecast in an earnings release, it is listed here with the exact sentence.